Treatment and Visual Outcomes in Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy: A Cohort Study

• Published in: Ocular immunology and inflammation 2024-12, Vol.32 (10), p.2441-2448
• Main Authors: Maccora, Ilaria, Ebert, Jared J, Schulert, Grant S, Quinlan-Waters, Megan, Duell, Alexandra, Huggins, Jennifer L, Sapp, Cameron C, Nguyen, Tiffany, Srivastava, Sunil K, Sood, Arjun B, Angeles-Han, Sheila T
• Format: Article
• Language: English
• Subjects: Adolescent; Calpain - genetics; Child; Familial Exudative Vitreoretinopathies - diagnosis; Female; Fluorescein Angiography; Follow-Up Studies; Glucocorticoids - therapeutic use; Humans; Immunosuppressive Agents - therapeutic use; Infliximab - therapeutic use; Male; Methotrexate - therapeutic use; Mutation; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity - physiology; Vitreoretinopathy, Proliferative - diagnosis; Vitreoretinopathy, Proliferative - drug therapy; Vitreoretinopathy, Proliferative - etiology; Vitreoretinopathy, Proliferative - genetics; Vitreoretinopathy, Proliferative - physiopathology
• ISSN: 0927-3948; 1744-5078; 1744-5078
• DOI: 10.1080/09273948.2024.2401146

Autosomal dominant neovascular inflammatory vitreoretinopathy (NIV), formerly called "ADNIV," is a rare autoinflammatory condition mainly of adulthood caused by mutations in calcium-activated calpain-5 protease (CAPN5). Our aim is to report the treatment and visual outcomes of children newly diagnosed with NIV after systemic treatment. We reviewed charts of patients ≤18 years old with CAPN5 gene mutation, ocular findings consistent with NIV, and treated with systemic immunosuppression for a minimum of 6 months. Treatment response was based on ophthalmic examination, ultra-widefield fluorescein-angiography (UWFFA), and optical coherence tomography (OCT). Eight children (16 eyes) were diagnosed with NIV at a median age of 14 (Range [R] 9-16) years, with a median follow-up of 18 months (R6-20). At diagnosis, one patient had impaired visual acuity (VA > 0.4), eight had vascular leakage, two had neovascularization, and three had macular edema. All responded to oral or local glucocorticoids but was not sustained. Systemic immunosuppression was started in seven patients with methotrexate and infliximab after a median time from diagnosis of 1.5 months (R0.5-2) and 3.2 months (R2.5-3.1), respectively. Infliximab was discontinued in all after a median time of 7 months (R3.5-10) for ineffectiveness, and 5/7 switched to tocilizumab and 1 to adalimumab. Five failed to respond (4 tocilizumab, 1 adalimumab) and one had a minimal response to tocilizumab. We report on the systemic treatment response of seven children with ADNIV treated with methotrexate, infliximab, and tocilizumab. None were able to control disease. Further studies are needed to understand long-term outcomes and the utility of systemic immunosuppression.